Mechanistic and Structural Basis for Inhibition of Copper Trafficking by Platinum Anticancer Drugs

被引:35
|
作者
Lasorsa, Alessia [1 ]
Nardella, Maria I. [1 ]
Rosato, Antonio [1 ]
Mirabelli, Valentina [2 ]
Caliandro, Rosanna [3 ,4 ]
Caliandro, Rocco [2 ]
Natile, Giovanni [1 ]
Arnesano, Fabio [1 ]
机构
[1] Univ Bari Aldo Moro, Dept Chem, Via Orabona 4, I-70125 Bari, Italy
[2] CNR, Inst Crystallog, Via Amendola 122-O, I-70126 Bari, Italy
[3] Free Univ Bolzano, Fac Sci & Technol, Bioorgan Chem & Biocrystallog Lab B 2 Cl, Piazza Univ 5, I-39100 Bolzano, Italy
[4] CNR, Inst Crystallog, Area Sci Pk Basovizza, I-34149 Trieste, Italy
关键词
CHAPERONE ATOX1; CELLULAR PHARMACOLOGY; ENDOPLASMIC-RETICULUM; TRANSPORT MECHANISMS; BINDING DOMAINS; CISPLATIN; PROTEIN; ATPASES; OXALIPLATIN; SENSITIVITY;
D O I
10.1021/jacs.9b05550
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Copper (Cu) is required for maturation of cuproenzymes, cell proliferation, and angiogenesis, and its transport entails highly specific protein-protein interactions. In humans, the Cu chaperone Atoxl mediates Cu(I) delivery to P-type ATPases Atp7a and Atp7b (the Menkes and Wilson disease proteins, respectively), which are responsible for Cu release to the secretory pathway and excess Cu efflux. Cu(I) handover is believed to occur through the formation of three-coordinate intermediates where the metal ion is simultaneously linked to Atoxl and to a soluble domain of Cu-ATPases, both sharing a CxxC dithiol motif. The ultrahigh thermodynamic stability of chelating S-donor ligands secures the redox-active and potentially toxic Cu(I) ion, while their kinetic lability allows facile metal transfer. The same CxxC motifs can interact with and mediate the biological response to antitumor platinum drugs, which are among the most used chemotherapeutics. We show that cisplatin and an oxaliplatin analogue can specifically bind to the heterodimeric complex Atox1-Cu(I)-Mnk1 (Mnk1 is the first soluble domain of Atp7a), thus leading to a kinetically stable adduct that has been structurally characterized by solution NMR and X-ray crystallography. Of the two possible binding configurations of the Cu(I) ion in the cage made by the CxxC motifs of the two proteins, one (bidentate Atoxl and monodentate Mnk1) is less stable and more reactive toward cis-Pt(II) compounds, as shown by using mutated proteins. A Cu(I) ion can be retained at the Pt(II) coordination site but can be released to glutathione (a physiological thiol) or to other complexing agents. The Pt(II)-supported heterodimeric complex does not form if Zn(II) is used in place of Cu(I) and transplatin instead of cisplatin. The results indicate that Pt(II) drugs can specifically affect Cu(I) homeostasis by interfering with the rapid exchange of Cu(I) between Atoxl and Cu-ATPases with consequences on cancer cell viability and migration.
引用
收藏
页码:12109 / 12120
页数:12
相关论文
共 50 条
  • [31] Nanocarrier delivery of platinum anticancer drugs
    Lippard, Stephen
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237 : 613 - 613
  • [32] Trans-platinum anticancer drugs
    Farrell, Nicholas
    CHEMISTRY WORLD, 2006, 3 (03): : 32 - 32
  • [33] MECHANISM OF ACTION OF PLATINUM ANTICANCER DRUGS
    ROSENBERG, B
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1982, 183 (MAR): : 5 - INOR
  • [34] Cellular processing of platinum anticancer drugs
    Dong Wang
    Stephen J. Lippard
    Nature Reviews Drug Discovery, 2005, 4 : 307 - 320
  • [35] Structural basis of γ-secretase inhibition and modulation by small molecule drugs
    Yang, Guanghui
    Zhou, Rui
    Guo, Xuefei
    Yan, Chuangye
    Lei, Jianlin
    Shi, Yigong
    CELL, 2021, 184 (02) : 521 - +
  • [36] Protein interaction with anticancer platinum drugs
    Li, Xing-Fang
    Mandal, Rupasri R.
    Sawyer, Michael B.
    CHEMICAL RESEARCH IN TOXICOLOGY, 2007, 20 (12) : 2014 - 2014
  • [37] NMR Spectroscopy of Anticancer Platinum Drugs
    Vinje, Jo
    Sletten, Einar
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2007, 7 (01) : 35 - 54
  • [38] Protein interaction with anticancer platinum drugs
    Li, Xing-Fang X. F.
    Mandal, Rupasri R.
    Sawyer, Michael B.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 234
  • [39] Nanocarriers for delivery of platinum anticancer drugs
    Oberoi, Hardeep S.
    Nukolova, Natalia V.
    Kabanov, Alexander V.
    Bronich, Tatiana K.
    ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (13-14) : 1667 - 1685
  • [40] Chiral discrimination in platinum anticancer drugs
    Benedetti, M
    Malina, J
    Kasparkova, J
    Brabec, V
    Natile, G
    ENVIRONMENTAL HEALTH PERSPECTIVES, 2002, 110 : 779 - 782